Since 2008, Dr. A. A. Bastian is working on natural product-based antibiotics as lead compounds and co-invented in total three technologies for the selective modification of structurally complex natural products.
Dr. A. A. Bastian studied Biomedical Chemistry at the University of Mainz in Germany and graduated with highest distinction in 2008. After his PhD studies (cum laude, 2012) at the University of Groningen, he received the Rubicon Research Grant from the Netherlands Organization for Research (NWO) to perform his postdoctoral studies at the University of Notre Dame in the United States.
In 2015, he was awarded the prestigious Veni Grant from NWO and started his own research at the University of Groningen focusing in novel antibacterials for the treatment of life-threatening Gram-negative infections. In 2017, Dr. A. A. Bastian co-founded AGILeBiotics and was appointed as managing director at the company for three years. Since April 2020, he is full-time employed as Chief Operating Officer leading the market development and the development of novel antibiotic candidates.